Geneva, Switzerland – Addex Therapeutics Ltd, a pharmaceutical company based in Geneva, Switzerland, held its Q3 2024 Earnings Conference Call on November 22, 2024. The call featured key company representatives including Tim Dyer, Co-Founder, Board Director, and Chief Executive Officer, alongside Mikhail Kalinichev, Head of Translational Science.

During the call, Dyer expressed gratitude to all participants for joining the conference to discuss the company’s financial results for the third quarter of 2024. He highlighted the availability of press releases and financial statements on the company’s website, urging attendees to review them. Dyer also emphasized the importance of acknowledging the forward-looking statements that would be made during the call.

In his address, Dyer provided an overview of recent activities and achievements, particularly focusing on the progress made in the company’s GABAB positive allosteric modulator program. He mentioned the completion of the R&D phase, which led to the development of multiple drug candidates. Additionally, Dyer highlighted the selection of a compound by partner Indivior for further development in substance use disorder, marking a significant milestone in the collaboration.

Following Dyer’s presentation, Kalinichev delved into a more detailed review of the GABAB PAM preclinical program, offering insights into the research and development process. The call also included a comprehensive review of Addex Therapeutics’ financial results for the third quarter of 2024, outlining key metrics and performance indicators.

Overall, Addex Therapeutics showcased substantial progress in its research programs and strategic partnerships, underscoring its commitment to advancing innovative therapies in the pharmaceutical industry. The conference call concluded with an interactive question-and-answer session, allowing participants to engage with company representatives and gain further clarity on pertinent issues.